Table 1.

The characters of included papers.

Study ID	Country	Study Type	Perspective	Study Method	Time Horizon (year)	Health State	Cost	Sensitivity Analysis
Delea 200734	US	CUA*	Health service	Markov model	50	β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death	direct medical cost: chelation, DFO administration, complication therapies(treatment of iron overload-related cardiac disease)	One-way & two-way & probabilistic
Luangasanatip 201135	Thailand	CUA	Society	Markov model	lifetime	β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death	direct medical cost: chelation, cost of a medical visit, DFO administration, adverse events management cost, complication therapies(treatment of iron overload-related cardiac disease) direct non-medical cost: transportation cost additional food cost, caregiver cost indirect cost: productivity	One-way & probabilistic
Karnon 201245	Australian	CUA	Health service	Markov model	50	β-thalassemia with cardiac and endocrine complications, β-thalassemia without cardiac and endocrine complications and death	direct medical cost: chelation, adverse events management cost, additional monitoring, complication therapies	One-way & Multi-way & probabilistic
Bentley 201346	UK	CUA	Health service	Markov model	5	β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death	direct medical cost: chelation, DFO administration, monitoring, adverse events management cost	One-way & two-way & probabilistic
Ho 201347	China Taiwan	CUA	Health service	Markov model	50	β-thalassemia with complications, β-thalassemia without complications and death	direct medical cost: chelation, DFO administration, complication therapies	One-way
Keshtkaran 201348	Iran	CUA	Society	Markov model	lifetime	β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death	direct medical cost: chelation, DFO administration, adverse events management cost, complication therapies(treatment of iron overload-related cardiac disease) indirect cost: transfusion time	One-way & probabilistic
Walczak 201349	Poland	CUA	NHF# & patient and NHF	Simple decision model	1	-	direct medical cost: chelation, DFO administration, Cost of hospitalizations for monitoring and blood transfusions, Cost of blood units, Cost of additional monitoring	-
Pepe 201750	Italy	CUA	Health service	Markov model	5	β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death	direct medical cost: chelation, DFO administration, monitoring	One-way & two-way & probabilistic

^*CUA: cost-utility analyses

^#NHF: Polish National Health Fund.